Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (Journal of Neurology, (2020), 267, 3, (703-712), 10.1007/s00415-019-09602-8)

Alejandra González-Duarte, John L. Berk, Dianna Quan, Michelle L. Mauermann, Hartmut H. Schmidt, Michael Polydefkis, Márcia Waddington-Cruz, Mitsuharu Ueda, Isabel M. Conceição, Arnt V. Kristen, Teresa Coelho, Cécile A. Cauquil, Céline Tard, Madeline Merkel, Emre Aldinc, Jihong Chen, Marianne T. Sweetser, Jing Jing Wang, David Adams

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original version of this article unfortunately contained a mistake in Table 1. Units for albumin were given as g/dL. It should be g/L.

Original languageEnglish (US)
Pages (from-to)713-714
Number of pages2
JournalJournal of Neurology
Volume267
Issue number3
DOIs
StatePublished - Mar 1 2020

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis (Journal of Neurology, (2020), 267, 3, (703-712), 10.1007/s00415-019-09602-8)'. Together they form a unique fingerprint.

Cite this